Zynerba halts development of THC prodrug ZYN001

This article was originally published here

A failure in a phase 1 clinical program has forced Zynerba Pharmaceuticals to stop development of ZYN001, its pro-drug of tetrahydrocannabinol (THC) intended for the treatment of neuropsychiatric disorders including Tourette Syndrome.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply